CD24: A Novel Surface Marker for PDX1-Positive Pancreatic Progenitors Derived from Human Embryonic Stem Cells

Abstract

Human ESCs provide a promising cell resource for the treatment of type I diabetes mellitus. Although PDX1-positive pancreatic progenitors can be efficiently generated from human ESCs by stepwise induction, further in vitro differentiation into functional, mature beta cells is not efficient or reproducible. Purification of pancreatic progenitor cells could facilitate the identification of signals that regulate beta cell differentiation and maturation. Here, we report the identification of a novel surface marker for PDX1-positive pancreatic progenitors based on an in vitro human ESC differentiation system. By costaining PDX1 and a panel of cell surface antigens at the pancreatic progenitor stage of human ESC differentiation, we discovered a positive marker, CD24. CD24-positive cells coexpressed most of the key transcription factors of pancreatic progenitors, and the expression of important pancreatic genes was greatly enriched in CD24-positive cells compared with the CD24-negative cells. In addition, CD24-positive cells could differentiate into insulin-producing cells but CD24-negative cells could not. These results indicate that CD24 could be a surface marker for PDX1-positive pancreatic progenitors derived from human ESCs. Enrichment of pancreatic progenitors with this marker will facilitate the investigation of beta cell maturation during the human ESC differentiation.

CD133 and CD24 expression in renal tissue of patients affected by autosomal dominant polcystic kidney disease

“…CD133 function is not clear but its presence on early and undifferentiated cells is suggestive of a growth factor receptor, and the presence of five tyrosine residues on the 50-aa cytoplasmic tail may indicate that the protein is phosphorylated in response to ligand binding and triggers a signal transduction [11]. CD24 is a sialoglycoprotein expressed on mature granulocytes [12], B and T lymphocyte subsets [13,14], normal and cancer stem cells [15,16]. The protein is anchored via a glycosyl phosphatidylinositol to cell surface.…”

Différenciation des cellules souches pluripotentes en cellules pancréatiques

“…Les facteurs de transcription permettant de marquer les différents lignages cellulaires sont mentionnés en bleu. ActA : activine A ; B27 : supplément B27 ; CpdE : inhibiteur de [30,39,40]. Même si les premiers travaux ont démontré l'absence de tératome après transplantation de cellules CD142 + [30], la spécificité de certains de ces marqueurs n'a pas été confirmée par d'autres chercheurs [39,41].…”

“…Beside many other strategies aiming at producing new beta cells in vitro or in vivo, a particular focus has been on the plupiropent stem cells because of their abundant availability and their extreme plasticity. Génération de cellules insuline + à partir de mESC [45] Endoderme définitif à partir de mESC [15] Endoderme définitif à partir de hESC [14] Dérivation de EpiSC (cellule souche épiblastique) de souris/rat [46,47] Dérivation de iPSC murines/humaines [48] Induction de progéniteurs pancréatiques à partir de hESC [20] Maturation de progéniteurs pancréatiques in vivo [22] Endoderme définitif dérivé avec des molécules de synthèse [18] Marqueurs de surface de progéniteurs pancréatiques [30,40] Production à large échelle de progéniteurs pancréatiques [34] Prolifération in vitro de progéniteurs pancréatiques [31,38] Tératocarcinome testiculaire Multipotentialité des cellules du carcinome embryonnaire Dérivation de ESC murines (m) [51,52] Dérivation de ESC humaines (h) [1] (➜) Voir l'article de A. Vieira et al, page 749 de ce numéro Progress in understanding small vertebrates embryonic development has tremendously contributed to the design of differentiation strategies applied to pluripotent stem cells. Nowadays, definitive endoderm and pancreatic progenitors can be efficiently induced from human embryonic stem cells and from human induced pluripotent stem cells.…”

Stem Cell Therapies for Type I Diabetes

“…Our group has analyzed the percentage of CD133 + CD49f low/+ cells during ESC-IPC differentiation following the Blyszczuk protocol, and we have detected an increase in the number of CD133 + CD49f low/+ cells in our cultures ( Figure 4A). CD24 , has been cited as a marker of murine pancreatic progenitors, and CD24 + cells isolated from human ESC-IPC express Pdx1, and express insulin after 1 week in vitro (Jiang, Sui et al 2011). …”